|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.40 EUR | -0.68% |
|
+9.55% | +72.91% |
| 12-04 | Evotec's Partner Bayer Starts Mid-stage Study of Genetic Kidney Disease Drug | MT |
| 12-04 | Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome | CI |
| Capitalization | 32.72B 38.06B 30.65B 28.57B 52.77B 3,426B 57.4B 359B 138B 1,618B 143B 140B 5,916B | P/E ratio 2025 * |
78x | P/E ratio 2026 * | 13.8x |
|---|---|---|---|---|---|
| Enterprise value | 64.54B 75.08B 60.46B 56.35B 104B 6,757B 113B 707B 273B 3,191B 282B 276B 11,668B | EV / Sales 2025 * |
1.41x | EV / Sales 2026 * | 1.34x |
| Free-Float |
100% | Yield 2025 * |
0.33% | Yield 2026 * | 1.62% |
Last Transcript: Bayer AG
| 1 day | -0.68% | ||
| 1 week | +9.55% | ||
| Current month | +9.55% | ||
| 1 month | +26.38% | ||
| 3 months | +18.61% | ||
| 6 months | +26.35% | ||
| Current year | +72.91% |
| 1 week | 30.16 |  | 35.02 |
| 1 month | 25.78 | | 35.02 |
| Current year | 18.38 | | 35.02 |
| 1 year | 18.38 | | 35.02 |
| 3 years | 18.38 | | 65.66 |
| 5 years | 18.38 | | 67.99 |
| 10 years | 18.38 | | 123.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 59 | 31/05/2023 |
| Director of Finance/CFO | 56 | 31/05/2018 | |
Christian Rommel
CTO | Chief Tech/Sci/R&D Officer | 58 | 31/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Achleitner
BRD | Director/Board Member | 69 | 31/03/2002 |
André van Broich
BRD | Director/Board Member | 55 | 31/03/2012 |
| Director/Board Member | 66 | 31/03/2022 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 9.77% | 0 M€ | -.--% | - |
| 4.28% | 962 M€ | -.--% | - |
| 4.1% | 1 M€ | +50.45% | - |
| 4.1% | 1 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.68% | +9.55% | +71.26% | -37.10% | 38.06B | |
| -0.41% | -6.06% | +22.37% | +173.58% | 905B | |
| -0.27% | -2.41% | +35.05% | +12.95% | 487B | |
| -1.15% | -0.71% | +28.33% | +37.90% | 400B | |
| +0.26% | +1.14% | +21.30% | +0.44% | 330B | |
| +0.58% | -2.73% | +28.01% | +20.71% | 281B | |
| +0.19% | +2.49% | +18.48% | +24.80% | 255B | |
| -1.16% | -4.87% | -3.70% | -9.35% | 248B | |
| +1.24% | -2.33% | -59.84% | -31.25% | 214B | |
| -3.02% | -4.51% | +20.25% | +15.79% | 178B | |
| Average | -0.25% | -1.04% | +18.15% | +20.85% | 333.46B | |
| Weighted average by Cap. | -0.10% | -2.65% | +18.23% | +54.92% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 45.73B 53.2B 42.84B 39.93B 73.76B 4,788B 80.22B 501B 193B 2,261B 200B 195B 8,269B | 46.11B 53.65B 43.2B 40.27B 74.37B 4,828B 80.89B 505B 195B 2,280B 201B 197B 8,338B |
| Net income | 746M 868M 699M 651M 1.2B 78.1B 1.31B 8.17B 3.16B 36.88B 3.26B 3.19B 135B | 2.53B 2.95B 2.37B 2.21B 4.09B 265B 4.45B 27.77B 10.72B 125B 11.07B 10.83B 458B |
| Net Debt | 31.82B 37.01B 29.8B 27.78B 51.31B 3,331B 55.81B 349B 135B 1,573B 139B 136B 5,752B | 29.19B 33.96B 27.35B 25.49B 47.08B 3,057B 51.21B 320B 124B 1,444B 127B 125B 5,278B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 33.30 € | -0.80% | 2,130,870 |
| 04/12/25 | 33.58 € | -1.97% | 2,917,912 |
| 03/12/25 | 34.25 € | +0.29% | 4,257,605 |
| 02/12/25 | 34.15 € | +12.08% | 10,883,080 |
| 01/12/25 | 30.47 € | -0.05% | 1,905,009 |
Delayed Quote Xetra, December 05, 2025 at 08:15 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BAYN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition